Abstract
Inhibition of the NLRP3 inflammasome is a promising strategy for the development of new treatments for inflammatory diseases. MCC950 is a potent and specific small-molecule inhibitor of the NLRP3 pathway, but its molecular target is not defined. Here, we show that MCC950 directly interacts with the Walker B motif within the NLRP3 NACHT domain, thereby blocking ATP hydrolysis and inhibiting NLRP3 activation and inflammasome formation.
Your institute does not have access to this article
Relevant articles
Open Access articles citing this article.
-
Acrylamide inhibits long-term potentiation and learning involving microglia and pro-inflammatory signaling
Scientific Reports Open Access 20 July 2022
-
Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases
Journal of Neuroinflammation Open Access 14 July 2022
-
The role of NLRP3 inflammasome in psychotropic drug-induced hepatotoxicity
Cell Death Discovery Open Access 09 July 2022
Access options
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$119.00
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.



Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Boucher, D. et al. J. Exp. Med. 215, 827–840 (2018).
Broz, P. & Dixit, V. M. Nat. Rev. Immunol. 16, 407–420 (2016).
Prochnicki, T., Mangan, M. S. & Latz, E. F1000Res. 5, 1469 (2016).
Guo, H., Callaway, J. B. & Ting, J. P. Nat. Med. 21, 677–687 (2015).
Broderick, L. et al. Annu. Rev. Pathol. 10, 395–424 (2015).
De Nardo, D., De Nardo, C. M. & Latz, E. Am. J. Pathol. 184, 42–54 (2014).
Coll, R. C. et al. Nat. Med. 21, 248–255 (2015).
van Hout, G. P. et al. Eur. Heart. J. 38, 828–836 (2017).
Primiano, M. J. et al. J. Immunol. 197, 2421–2433 (2016).
Kim, R. Y. et al. Am. J. Respir. Crit. Care Med. 196, 283–297 (2017).
Tate, M. D. et al. Sci. Rep. 6, 27912 (2016).
Kammoun, H. L. et al. Mol. Metab. 10, 66–73 (2018).
Moffat, J. G. et al. Nat. Rev. Drug Discov. 16, 531–543 (2017).
Gross, C. J. et al. Immunity 45, 761–773 (2016).
Gaidt, M. M. et al. Immunity 44, 833–846 (2016).
Shi, H. et al. Nat. Immunol. 17, 250–258 (2016).
White, C. S., Lawrence, C. B., Brough, D. & Rivers-Auty, J. Brain Pathol. 27, 223–234 (2017).
Van Gorp, H. et al. Proc. Natl Acad. Sci. USA 113, 14384–14389 (2016).
Lomenick, B. et al. Proc. Natl Acad. Sci. USA 106, 21984–21989 (2009).
Schroder, K. & Tschopp, J. Cell 140, 821–832 (2010).
Duncan, J. A. et al. Proc. Natl Acad. Sci. USA 104, 8041–8046 (2007).
Hu, Z. et al. Science 341, 172–175 (2013).
Tenthorey, J. L. et al. Science 358, 888–893 (2017).
Wendler, P., Ciniawsky, S., Kock, M. & Kube, S. Biochim. Biophys. Acta 1823, 2–14 (2012).
Tapia-Abellán, A. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0278-6 (2019).
Mariathasan, S. et al. Nature 430, 213–218 (2004).
Schroder, K. et al. Proc. Natl Acad. Sci. USA 109, E944–E953 (2012).
Lomenick, B., Jung, G., Wohlschlegel, J. A. & Huang, J. Curr. Protoc. Chem. Biol. 3, 163–180 (2011).
Pai, M. Y. et al. Methods Mol. Biol. 1263, 287–298 (2015).
Xu, C. P. et al. Chem. Biol. 16, 980–989 (2009).
Mackinnon, A. L. & Taunton, J. Curr. Protoc. Chem. Biol. 1, 55–73 (2009).
Stols, L. et al. Protein Expr. Purif. 25, 8–15 (2002).
Acknowledgements
This work was supported by the National Health and Medical Research Council of Australia (Fellowship 1138466 and Program Grant no. 1071659 to M.P.J.; Fellowship no. 1141131 to K.S.; Project Grant no. 1086786 to A.A.B.R. and K.S.), the Australian Research Council (Fellowship no. FT130100361 to K.S.), the Institute for Molecular Bioscience (Research Advancement Award to J.H.) and The University of Queensland (Postdoctoral Fellowships to R.C.C. and D.B.; Research Scholarship to J.H.). We thank D. Edwards for chemical purification and analytical support, M. Cooper (University of Queensland) for providing MCC950 and K. Stacey (University of Queensland) for providing ASC-deficient mice.
Author information
Authors and Affiliations
Contributions
R.C.C. designed and performed most experiments. J.R.H. conceived and synthesized the photoaffinity probe and performed labeling experiments. C.J.D. and M.P.J. designed and performed SPR analysis. A.Z. designed and cloned the NLRP3 expression plasmids and mutants. D.B. expressed and purified recombinant NLRP3 and assisted with experimental design. N.L.M synthesized the photoaffinity probe. J.L.C. and J.A.F. assisted with the expression and purification of recombinant NEK7, A.A.B.R. formulated MCC950, conceived the photoaffinity probe and expressed and purified recombinant NEK7. A.A.B.R. and K.S. designed experiments and supervised the study. R.C.C and K.S wrote the manuscript, with assistance from J.R.H. and A.A.B.R. and input from all authors.
Corresponding authors
Ethics declarations
Competing interests
R.C.C., A.A.B.R. and K.S. are co-inventors on patent applications for NLRP3 inhibitors (WO2018215818, WO2017140778 and WO2016131098), which are licensed to Inflazome Ltd, a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Table 1, Supplementary Figures 1–15
Supplementary Note
Synthetic Procedures
Rights and permissions
About this article
Cite this article
Coll, R.C., Hill, J.R., Day, C.J. et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol 15, 556–559 (2019). https://doi.org/10.1038/s41589-019-0277-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-019-0277-7
Further reading
-
Dihydromyricetin alleviates Escherichia coli lipopolysaccharide-induced hepatic injury in chickens by inhibiting the NLRP3 inflammasome
Veterinary Research (2022)
-
Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases
Journal of Neuroinflammation (2022)
-
Context-dependent functions of pattern recognition receptors in cancer
Nature Reviews Cancer (2022)
-
Acrylamide inhibits long-term potentiation and learning involving microglia and pro-inflammatory signaling
Scientific Reports (2022)
-
The role of NLRP3 inflammasome in psychotropic drug-induced hepatotoxicity
Cell Death Discovery (2022)